Tumor-suppressive microRNA-145 induces growth arrest by targeting SENP1 in human prostate cancer cells

Cancer Science

Volumn 106, Issue 4, 2015, Pages 375-382

  Wang, Chunyang ^a   Tao, Weiyang ^b   Ni, Shaobin ^a   Chen, Qiyin ^a   Zhao, Zhongshan ^a   Ma, Li ^a   Fu, Yiming ^a   Jiao, Zhixing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Gene regulation; MiR 145; Prostate cancer; SENP1; Tumorigenesis

Indexed keywords

MESSENGER RNA; MICRORNA 145; SMALL UBIQUITIN LIKE MODIFIER SPECIFIC PROTEASE 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MICRORNA; MIRN145 MICRORNA, HUMAN; PROTEIN BINDING; PROTEINASE; SENP1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; GROWTH DISORDER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INVESTIGATIVE PROCEDURES; LNCAP CELL LINE; LUCIFERASE ASSAY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INTERACTION; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL CYCLE CHECKPOINT; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

3' UNTRANSLATED REGIONS; ANIMALS; BINDING SITES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; ENDOPEPTIDASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PROTEIN BINDING; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 84928031987     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12626     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-36.
3. Zhang L, Wu S, Guo LR, Zhao XJ. Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China. Asian J Androl 2009; 11: 9-13.
4. Gallagher RP, Fleshner N. Prostate cancer: 3. Individual risk factors. CMAJ 1998; 159: 807-13.
5. Bawa-Khalfe T, Cheng J, Wang Z, Yeh ET. Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. J Biol Chem 2007; 282: 37341-9.
6. Jin M, Zhang T, Liu C et al. miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells. Cancer Res 2014; 74: 4183-95.
7. Wang LN, Chen WW, Zhang J et al. The miRNA let-7a1 inhibits the expression of insulin-like growth factor 1 receptor (IGF1R) in prostate cancer PC-3 cells. Asian J Androl 2013; 15: 753-8.
8. Ulrich HD. The fast-growing business of SUMO chains. Mol Cell 2008; 32: 301-5.
9. Mukhopadhyay D, Dasso M. Modification in reverse: the SUMO proteases. Trends Biochem Sci 2007; 32: 286-95.
10. Wen D, Xu Z, Xia L et al. Important role of SUMOylation of spliceosome factors in prostate cancer cells. J Proteome Res 2014; 13: 3571-82.
11. Xu Y, Li J, Zuo Y, Deng J, Wang LS, Chen GQ. SUMO-specific protease 1 regulates the in vitro and in vivo growth of colon cancer cells with the upregulated expression of CDK inhibitors. Cancer Lett 2011; 309: 78-84.
12. Cheng J, Bawa T, Lee P, Gong L, Yeh ET. Role of desumoylation in the development of prostate cancer. Neoplasia 2006; 8: 667-76.
13. Bawa-Khalfe T, Yeh ET. SUMO losing balance: SUMO proteases disrupt SUMO homeostasis to facilitate cancer development and progression. Genes Cancer 2010; 1: 748-52.
14. Bawa-Khalfe T, Cheng J, Lin SH, Ittmann MM, Yeh ET. SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. J Biol Chem 2010; 285: 25859-66.
15. Li T, Huang S, Dong M, Gui Y, Wu D. Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy. Urol Oncol 2013; 31: 1539-45.
16. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
17. Calin GA, Sevignani C, Dumitru CD et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004; 101: 2999-3004.
18. Noonan EJ, Place RF, Pookot D et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009; 28: 1714-24.
19. Ribas J, Ni X, Haffner M et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009; 69: 7165-9.
20. Sachdeva M, Mo YY. miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res 2010; 2: 170-80.
21. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27: 1788-93.
22. Wach S, Nolte E, Szczyrba J et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer 2012; 130: 611-21.
23. Law PT, Ching AK, Chan AW et al. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis 2012; 33: 1134-41.
24. Cho WC, Chow AS, Au JS. MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol 2011; 8: 125-31.
25. Thomsen MK, Ambroisine L, Wynn S et al. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res 2010; 70: 979-87.
26. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62: 2942-50.
27. Karan D, Lin FC, Bryan M et al. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int J Oncol 2003; 23: 1365-71.
28. Wafa LA, Cheng H, Plaa N et al. Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression. Int J Cancer 2012; 130: 2835-44.
29. Tian Y, Luo A, Cai Y et al. MicroRNA-10b promotes migration and invasion through KLF4 in human esophageal cancer cell lines. J Biol Chem 2010; 285: 7986-94.
30. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
31. Volinia S, Calin GA, Liu CG et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006; 103: 2257-61.
32. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1: 882-91.
33. Iorio MV, Visone R, Di Leva G et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67: 8699-707.
34. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130-5.
35. Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9: 189-98.
36. Schepeler T, Reinert JT, Ostenfeld MS et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008; 68: 6416-24.
37. Sempere LF, Christensen M, Silahtaroglu A et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007; 67: 11612-20.
38. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R. Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 2007; 282: 32582-90.
39. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
40. Carroll AG, Voeller HJ, Sugars L, Gelmann EP. p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993; 23: 123-34.
41. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009; 137: 647-58.
42. Wang S, Bian C, Yang Z et al. miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 2009; 34: 1461-6.
43. Gong L, Millas S, Maul GG, Yeh ET. Differential regulation of sentrinized proteins by a novel sentrin-specific protease. J Biol Chem 2000; 275: 3355-9.
44. Cheng J, Wang D, Wang Z, Yeh ET. SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol 2004; 24: 6021-8.
45. Chen Y, Martinez LA, LaCava M, Coghlan L, Conti CJ. Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene 1998; 16: 1913-20.
46. Comstock CE, Revelo MP, Buncher CR, Knudsen KE. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br J Cancer 2007; 96: 970-9.